Treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD medicinal products in mid to late stage fluctuating patients
Central nervous system
Safinamide is not recommended for the treatment of patients with Parkinson’s disease. Evidence to support efficacy is not adequate to support a recommendation to prescribe.The drug is more expensive than others in its class and a favourable cost/benefit profile cannot be calculated for the drug.There are established options for treating patients at the late stage of their condition including two drugs currently supported that fall into the MAO‑B category.
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria